OA09809A - Mococlonal antibodies to ELAM-1 and their uses. - Google Patents

Mococlonal antibodies to ELAM-1 and their uses.

Info

Publication number
OA09809A
OA09809A OA60394A OA60394A OA09809A OA 09809 A OA09809 A OA 09809A OA 60394 A OA60394 A OA 60394A OA 60394 A OA60394 A OA 60394A OA 09809 A OA09809 A OA 09809A
Authority
OA
OAPI
Prior art keywords
mococlonal
elam
antibodies
mococlonal antibodies
Prior art date
Application number
OA60394A
Inventor
Elisabeth Wayner
Mary L Phillips
Jeffrey L Winkelhake
Original Assignee
Cytel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytel Corp filed Critical Cytel Corp
Publication of OA09809A publication Critical patent/OA09809A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
OA60394A 1991-01-24 1993-07-22 Mococlonal antibodies to ELAM-1 and their uses. OA09809A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64587891A 1991-01-24 1991-01-24
US73303391A 1991-07-22 1991-07-22

Publications (1)

Publication Number Publication Date
OA09809A true OA09809A (en) 1994-04-15

Family

ID=27094802

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60394A OA09809A (en) 1991-01-24 1993-07-22 Mococlonal antibodies to ELAM-1 and their uses.

Country Status (11)

Country Link
EP (1) EP0568631A4 (en)
JP (1) JPH06505253A (en)
AU (1) AU1269092A (en)
CA (1) CA2100681A1 (en)
IE (1) IE920206A1 (en)
IL (1) IL100764A0 (en)
NO (1) NO932672L (en)
NZ (1) NZ241399A (en)
OA (1) OA09809A (en)
SK (1) SK77393A3 (en)
WO (1) WO1992012729A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
EP0602290B1 (en) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5723116A (en) * 1995-01-06 1998-03-03 University Of South Florida Decreased mortality of severe acute pancreatitis following proximal cytokine blockade
AU6155896A (en) * 1995-06-07 1996-12-30 Cytel Corporation Humanized antibodies to e-selectin
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
AU750414B2 (en) 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
CA2349501A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
EP1140864A2 (en) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
JP2012500652A (en) * 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Targeted costimulatory polypeptides and methods of use for treating cancer
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
WO2019151418A1 (en) 2018-01-31 2019-08-08 元一 加藤 Therapeutic agent for asthma containing il-6 inhibitor
WO2020213665A1 (en) 2019-04-17 2020-10-22 国立大学法人広島大学 Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
EP4093508A1 (en) 2020-01-24 2022-11-30 Pfizer Inc. Anti-e-selectin antibodies, compositions and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005539A1 (en) * 1988-11-14 1990-05-31 Brigham And Women's Hospital Antibodies specific for elam-1 and the use thereof
US5081034A (en) * 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)

Also Published As

Publication number Publication date
CA2100681A1 (en) 1992-07-25
IL100764A0 (en) 1992-09-06
JPH06505253A (en) 1994-06-16
NZ241399A (en) 1994-06-27
NO932672D0 (en) 1993-07-23
EP0568631A4 (en) 1995-04-05
AU1269092A (en) 1992-08-27
SK77393A3 (en) 1994-12-07
WO1992012729A1 (en) 1992-08-06
NO932672L (en) 1993-09-23
EP0568631A1 (en) 1993-11-10
IE920206A1 (en) 1992-07-29

Similar Documents

Publication Publication Date Title
IL100764A0 (en) Monoclonal antibodies to elam-1 and their uses
IL101690A0 (en) Antibodies and methods utilizing the same
ZW9091A1 (en) Oxamides
EP0653265A3 (en) Improvements relating to friction welding.
EP0804235A4 (en) Antibodies to p-selectin and their uses
ZA943110B (en) Peptides and compounds that bind to elam-1.
EP0437959A3 (en) Clip
GB9208278D0 (en) Improvements relating to closures
EP0646014A4 (en) The use of hyperimmune milk to increase longevity.
GB2240807B (en) Clip
GB2248775B (en) Clip
GB2284404B (en) Improvements to ID systems
HU9503156D0 (en) Antibodies to p-selectin and their uses
GB9223676D0 (en) Modified antibodies
ZA92468B (en) Monoclonal antibodies to ELAM-1 and their uses
GB9115010D0 (en) Antibody
GB9105532D0 (en) Antibody production
GB2253796B (en) Improvements relating to swings and the like
GB9207973D0 (en) Improvements relating to telecines and the like
GB9115498D0 (en) Utility
ZA922978B (en) Novel antibodies and methods for their use.
HU912512D0 (en) Nonorganic based enzyme-carrier, and the enzymes bound to the carrier
GB9124953D0 (en) Improvements to auto-refractors
HU912038D0 (en) Wc-flushing system with double contanier
GB9025482D0 (en) Improvements to auto-refractors